NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

Core Insights - Nanobiotix is presenting updated data from Study 1100, a Phase 1 trial evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer, at ASCO 2024 [1][2] - The company will host an investor event on June 2, 2024, to discuss the results presented at ASCO [1][3] Study Details - Study 1100 includes 68 patients, with early signs of efficacy observed in both anti-PD-1 naïve (n=33) and anti-PD-1 resistant (n=35) head and neck squamous cell carcinoma (HNSCC) [2] - NBTXR3 is a novel oncology product composed of functionalized hafnium oxide nanoparticles, administered via intratumoral injection and activated by radiotherapy [4] Product Development - NBTXR3 is being evaluated across multiple solid tumor indications, including a global Phase 3 study in locally advanced HNSCC [5] - The FDA granted Fast Track designation for NBTXR3 activated by radiation therapy for patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy [5] Collaboration and Strategy - Nanobiotix has engaged in a collaboration strategy to expand the development of NBTXR3, including a partnership with The University of Texas MD Anderson Cancer Center for several Phase 1 and Phase 2 studies [6] - In 2023, the company announced a license agreement for global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV [6] Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on innovative therapeutic approaches to improve treatment outcomes for cancer patients [7] - The company is headquartered in Paris, France, and is listed on Euronext Paris and NASDAQ [8]